Imdelltra (Tarlatamab-Dlle): A Breakthrough In Treating Extensive-Stage Small Cell Lung Cancer
Imdelltra™ (tarlatamab-dlle) represents a significant advancement in the treatment of extensive-stage small cell lung cancer (ES-SCLC), a particularly aggressive form of lung cancer.
Developed by Amgen, this novel therapy received accelerated approval from the U.S. Food and Drug Administration (FDA) on May 16, 2024, offering new hope to patients who have experienced disease progression following platinum-based chemotherapy.
Imdelltra Mechanism Of Action
Imdelltra is a bispecific T-cell engager (BiTE) antibody construct designed to direct the body’s immune system to target and destroy cancer cells. Specifically, it binds to delta-like ligand 3 (DLL3), a protein expressed on the surface of SCLC cells, and CD3, a component of T-cells. By bridging these two cell types, Imdelltra facilitates the activation of T-cells to attack and eliminate DLL3-expressing tumor cells.
Clinical Efficacy
The FDA’s accelerated approval was based on results from the Phase 2 DeLLphi-301 clinical trial, which evaluated Imdelltra in patients with ES-SCLC who had progressed after platinum-based chemotherapy.
In this study, Imdelltra demonstrated a 40% objective response rate (ORR), with a median duration of response (DoR) of 9.7 months and a median overall survival of 14.3 months.
Dosage And Administration
Imdelltra is administered intravenously with a step-up dosing schedule to mitigate the risk of cytokine release syndrome (CRS). The recommended regimen involves an initial dose of 1 mg on Day 1 of Cycle 1, followed by 10 mg doses on Days 8 and 15, and then every two weeks thereafter.
Prior to each dose, patients should be evaluated for complete blood count, liver enzymes, and bilirubin levels. Ensuring patients are well-hydrated before administration is also advised.
Safety Profile
While Imdelltra offers promising efficacy, it is associated with potential adverse reactions. The most common side effects include fatigue, fever, decreased appetite, musculoskeletal pain, and constipation.
Serious adverse events such as CRS and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), have been reported. Healthcare providers should monitor patients closely for these reactions and manage them promptly.
Conclusion
Imdelltra’s approval marks a significant milestone in the treatment of ES-SCLC, providing a novel therapeutic option for patients with limited alternatives.
Its unique mechanism of action and demonstrated clinical benefits underscore its potential to improve outcomes in this challenging disease. Ongoing studies will further elucidate its role in earlier stages of SCLC and its long-term efficacy and safety profile.
About DengYueMed – HK Drug Wholesale Distributor
As a legally compliant drug import and export company, DengYueMed is certified by the pharmacy & poisons board of Hong Kong — you can verify our qualification on their official website.
Our efforts to improve the affordability of Tarlatamab-Dlle drug aim to ensure that more patients can benefit from this important medication.
HK DengYue provides detailed medicine information, transparent pricing, and responsive support to ensure a smooth and reliable buying experience.
Feel free to reach out anytime to discuss your needs or ask questions about the medicine. We welcome you to contact us for a consultation.
